Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration.
The author presents six cases which suggest a palliative effect of combination amantadine/neuroleptic in tardive dyskinesia. The six patients all met criteria for definite tardive dyskinesia, and did not have coexistent pseudoparkinsonism. Serial addition and subtraction of amantadine with fixed low-dose neuroleptic points to a specific amantadine effect. Previous studies are reviewed and speculation about the mechanism of action of the combination is discussed.
D000328:Adult; D000368:Aged; D000547:Amantadine / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects; D003704:Dementia / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D019965:Neurocognitive Disorders / Q000188:drug therapy*; D010166:Palliative Care / Q000379:methods*; D012559:Schizophrenia / Q000188:drug therapy*; D012563:Schizophrenia, Paranoid / Q000188:drug therapy; D013881:Thioridazine / Q000627:therapeutic use
D014150:Antipsychotic Agents; D000547:Amantadine; D006220:Haloperidol; D013881:Thioridazine